A Pharmacokinetic Evaluation of Two Nicotine Patches in Smokers
NCT ID: NCT01702519
Last Updated: 2015-03-20
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
40 participants
INTERVENTIONAL
2012-03-31
2012-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Nicotine Patch - Multidose Bioequivalence Study
NCT01658215
Nicotine Patch Bioequivalence Study
NCT01658202
Nicotine Patch - Bioequivalence Study
NCT02089308
Safety, Tolerability and Efficacy of the Nicotine Patch and Gum for the Treatment of Adolescent Tobacco Dependence
NCT01208935
Bioequivalence Between Two Oral Nicotine Sublingual Tablets, 2 mg and 4 mg
NCT01238627
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Reference
nicotine transdermal patch with the existing polyisobutylene adhesive
nicotine
nicotine transdermal patch
Treatement
nicotine transdermal patch with the alternate polyisobutylene adhesive
nicotine
nicotine transdermal patch
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
nicotine
nicotine transdermal patch
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* smokes \>10 cigarettes per day for preceeding 6 months
Exclusion Criteria
19 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Celerion NEBRASKA
Lincoln, Nebraska, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RH01418
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.